Pfizer (PFE) and Seagen (SGEN) will receive a second request from the Federal Trade Commission in relation to their proposed tie-up, two sources familiar with the matter told Dealreporter, which notes that the waiting period under the HSR Act related to their merger filing is due to expire at the end of today, July 14.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seattle Genetics put volume heavy and directionally bearish
- Seagen reports progression free survival data from Adcetris combination study
- Seagen Posts Impressive Phase 2 Data in Hodgkin Lymphoma
- Seagen announces updated efficacy, safety results from Part C of Adcetris study
- Pfizer Stock (NYSE:PFE) – New FDA Approval Could Stop Its Drop